WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

  • WJPPS: APRIL ISSUE PUBLISHED
  • April Issue has been successfully launched on 1 April 2024.

Abstract

A RECENT REVIEW: JAPANESE ENCEPHALITIS

Hembade Mahendra*, Gaikwad Yogesh, Lukkad Harish, Kangane Monika, Dr. Sathesh Kumar

ABSTRACT

Japanese encephalitis (JE) is the most common form of viral encephalitis that appears in the form of frequent epidemics of brain fever throughout Southeast Asia, China and India. The disease is caused by a Flavivirus named Japanese encephalitis virus that is spread to humans by mosquitoes., Union health minister Ghulam Nabi Azad launched India’s first indigenously prodcued vaccine against Japanese Encephalitis (JE), a mosquito-borne viral infection that affects the central nervous system. Bharat Biotech launch of its Vero cell-derived purified inactivated JE vaccine “JENVAC™” which received the manufacturing and marketing approvals by Drug Controller General of India (DCGI). It is a fully indigenous vaccine commercialized using strain, identified, characterized, manufactured and tested in India. JENVAC is a purified Inactivated Japanese Encephalitis vaccine produced from an Indian thermally stable strain, 821564-XY.JENVAC® is indicated for the prevention of disease caused by Japanese encephalitis virus (JEV) in persons 1 year of age and older. It is a Vero cell derived, inactivated, and chromatographically purified Japanese encephalitis vaccine and is made from a thermally stable India strain, Kolar, 821564-XY. The vaccine must be administered intramuscularly. JENVAC is the first vaccine to be manufactured in the public-private partnership mode. These new candidate JE vaccines have the potential to generate long-lasting immunity at low cost.

Keywords: Encephalitis, JENVAC, vaccine.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More